Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
540.28B
Market cap540.28B
Price-Earnings ratio
26.67
Price-Earnings ratio26.67
Dividend yield
2.25%
Dividend yield2.25%
Average volume
8.39M
Average volume8.39M
High today
$227.48
High today$227.48
Low today
$224.06
Low today$224.06
Open price
$226.50
Open price$226.50
Volume
3.29M
Volume3.29M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$146.12
52 Week low$146.12

Stock Snapshot

With a market cap of 540.28B, Johnson & Johnson(JNJ) trades at $224.31. The stock has a price-to-earnings ratio of 26.67 and currently yields dividends of 2.3%.

On 2026-04-22, Johnson & Johnson(JNJ) stock traded between a low of $224.06 and a high of $227.48. Shares are currently priced at $224.31, which is +0.1% above the low and -1.4% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 3.29M, against a daily average of 8.39M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $251.71 and a 52-week low of $146.12.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $251.71 and a 52-week low of $146.12.

JNJ News

TipRanks 4h
Johnson & Johnson reports new data from Phase 3 Vivacity-MG3 study

Johnson & Johnson announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension, or OLE, in a broad population of antibody-positive, o...

Nasdaq 5h
J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?

Johnson & Johnson JNJ, via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiova...

J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?
TipRanks 6h
MeiraGTx price target raised to $30 from $26 at Piper Sandler

Piper Sandler raised the firm’s price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company’s long-term d...

Analyst ratings

59%

of 29 ratings
Buy
58.6%
Hold
34.5%
Sell
6.9%

More JNJ News

Simply Wall St 18h
A Look At Johnson & Johnson Valuation After Recent Share Price Weakness

Johnson & Johnson (JNJ) stock is drawing attention after recent trading left shares around $226.16, with a 1 day return of about a 2% decline and a past week mo...

A Look At Johnson & Johnson Valuation After Recent Share Price Weakness
24/7 Wall St. 22h
GDV's 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn By David Beren Published Apr 21, 3:34PM EDT Quick Read Gabelli Dividend & Income Trust (GDV) t...

GDV's 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn
The Motley Fool 1d
Anika Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, July 30, 2025 at 8:30 a.m. ET Call participants President and Chief Executive Officer — Cheryl Renee Blanchard, Ph.D....

Anika Q2 2025 Earnings Call Transcript
TipRanks 1d
Johnson & Johnson to showcase electrophysiology portfolio at HRS meeting

Johnson & Johnson will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society Annual Meeting, including new eviden...

Sherwood News 1d
Psychedelic biotechs inch toward commercialization with Trump’s blessing

Biotechs working on psychedelic-based treatments have long been a staple in retail investors portfolios. Now, several are poised to gain federal approval, poten...

Psychedelic biotechs inch toward commercialization with Trump’s blessing
24/7 Wall St. 2d
Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter

Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter By Vandita Jadeja Published Apr 20, 12:35PM EDT Quick Read Johnson & Johnson (JNJ),...

Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter
Investor's Business Daily 2d
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others

Technology Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others Licensing Eli Lilly (LLY) said Monday it will spend up to $7 billion to buy priva...

Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.